Congressional concern growing over integration of Chinese, U.S. biopharma 

Bipartisan legislation targeting biotechnology under the U.S. outbound investment screening regime seeks to create a new set of restrictions on future U.S. engagement with Chinese biopharma. While the intent is to prevent U.S. companies from in-licensing Chinese biomedical products, the bill would give the Treasury Department discretion to determine which transactions would be prohibited.

The more immediate significance of the Biotech Investment National Security Act (BINSA) may lie less in its prospects for passage than in the pressure it exerts on Treasury’s pending rulemaking. ...